EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnostic Value of Karyotype, Microarray, RASopathy Gene Testing and Ultrasound in Fetuses with Nuchal Translucency 3.0–3.4 mm: A Single-Center Cohort Retrospective Study

Silvia Andrietti, Giuseppe Gullo iD, Diliana Beleva, Alessia Maccarrone iD, Lina De Paola iD, Chiara Roberta Gaggero, Chiara Calcagno, Maria Lucia Furnari, Pierangela De Biasio

Genes · 2026

DOI: 10.3390/genes17020234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Silvia Andrietti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Prenatal Diagnosis and Perinatal Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy. Hauptthemen laut MEDLINE: Nuchal Translucency Measurement, Genetic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increased nuchal translucency (NT) is associated with an elevated risk of genetic abnormalities and structural malformations. The clinical utility of invasive testing and the optimal diagnostic approach in mildly increased NT (3.0–3.4 mm) is debated. This study aimed to evaluate genetic and ultrasound findings in this subgroup and to assess the diagnostic yield of advanced genetic testing.

Methods

We retrospectively included a total of 107 fetuses with NT between 3.0 and 3.4 mm from a single fetal medicine unit. Complete outcome data were available for 97 pregnancies. Invasive prenatal testing with standard karyotype, chromosomal microarray analysis (CMA) and RASopathy panel testing were offered. All patients underwent detailed ultrasound examination to detect structural abnormalities at 16 and 20 weeks, regardless of whether invasive testing was performed.

Results

Invasive prenatal testing, amniocentesis or chorionic villus sampling, (CVS), was performed in 77/97 cases (79.4%). Genetic abnormalities were detected in 28/97 (28.9%). Overall, five rare genetic anomalies were identified; none would have been detected by quantitative fluorescent polymerase chain reaction (QF-PCR) or non-invasive prenatal testing (NIPT). Two anomalies were detectable by standard karyotype, two exclusively by CMA and one exclusively by RASopathy panel. When considering all cases undergoing advanced genetic testing (CMA or RASopathy panel, n = 35) the overall diagnostic yield was 8.5% (3/35). When calculated across the entire cohort with complete follow-up, the additional diagnostic yield was 3.1% (3/97). Major structural malformations were identified in 17/97 cases (17.5%), of which 10 (58.8%) were associated with genetic abnormalities.

Conclusions

Fetuses with NT measurements between 3.0 and 3.4 mm show a substantially increased risk of genetic abnormalities and structural malformations. These findings support a comprehensive prenatal evaluation, including invasive testing with advanced genetic analysis and detailed ultrasound assessment, to optimize diagnosis and counseling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuchal Translucency MeasurementGenetic TestingHumansFemalePregnancyRetrospective StudiesKaryotypingAdultKaryotypeUltrasonography, PrenatalMicroarray AnalysisChorionic Villi SamplingChromosome AberrationsPrenatal DiagnosisFetus

Stichwörter der Autor:innen

RASopathieschromosomal abnormalitieschromosomal microarrayfirst-trimester screeningnuchal translucencyprenatal diagnosis

Autor:innen und Institutionen

  • Prenatal Diagnosis and Perinatal Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
  • Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, University of Palermo, 90146 Palermo, Italy.
  • Department of Neurology, Rehabilitation, Ophtalmology, Genetics, Maternal and Infant Health (DiNOGMI), 16132 Genoa, Italy.
  • Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, 00161 Rome, Italy.
  • AOOR Villa Sofia-Cervello, 90146 Palermo, Italy.

ORCID-Profile: Giuseppe Gullo, Alessia Maccarrone, Lina De Paola

Zitieren

APA

Andrietti, S., Gullo, G., Beleva, D., Maccarrone, A., De Paola, L., Gaggero, C. R., Calcagno, C., Furnari, M. L., & Biasio, P. (2026). Diagnostic Value of Karyotype, Microarray, RASopathy Gene Testing and Ultrasound in Fetuses with Nuchal Translucency 3.0–3.4 mm: A Single-Center Cohort Retrospective Study. Genes. https://doi.org/10.3390/genes17020234

Vancouver

Andrietti S, Gullo G, Beleva D, Maccarrone A, De Paola L, Gaggero CR, et al. Diagnostic Value of Karyotype, Microarray, RASopathy Gene Testing and Ultrasound in Fetuses with Nuchal Translucency 3.0–3.4 mm: A Single-Center Cohort Retrospective Study. Genes. 2026. doi:10.3390/genes17020234

BibTeX
@article{Andrietti2026,
  author = {Andrietti, Silvia and Gullo, Giuseppe and Beleva, Diliana and Maccarrone, Alessia and De Paola, Lina and Gaggero, Chiara Roberta and Calcagno, Chiara and Furnari, Maria Lucia and Biasio, Pierangela De},
  title = {Diagnostic Value of Karyotype, Microarray, RASopathy Gene Testing and Ultrasound in Fetuses with Nuchal Translucency 3.0–3.4 mm: A Single-Center Cohort Retrospective Study},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17020234}
}
Kostenlos starten →